Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma Key events in the progression from an in situ to an invasive breast carcinoma

Cell Cycle

Volumn 12, Issue 16, 2013, Pages 2684-2690

  Martins, Diana ^a   Beça, Francisco F ^a,b   Sousa, Bárbara ^a   Baltazar, Fátima ^c,d   Paredes, Joana ^a,b   Schmitt, Fernando ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF MINHO   (Portugal)

Author keywords

Breast cancer; Caveolin 1; DCIS; IDC; Immunohistochemistry; MCT4; Stroma; Tumor progression

Indexed keywords

CAVEOLIN 1; MONOCARBOXYLATE TRANSPORTER 4;

ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CARCINOMA IN SITU; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

BREAST CANCER; CAVEOLIN-1; DCIS; IDC; IMMUNOHISTOCHEMISTRY; MCT4; STROMA; TUMOR PROGRESSION; TUMOUR PROGRESSION;

BREAST NEOPLASMS; CAVEOLIN 1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; NEOPLASM INVASIVENESS; TUMOR MICROENVIRONMENT;

EID: 84883237456     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25794     Document Type: Article

References (32)

1. Knudsen ES, Ertel A, Davicioni E, Kline J, Schwartz GF, Witkiewicz AK. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat 2012; 133:1009-24; PMID:22134623; http://dx.doi.org/10.1007/s10549-011-1894-3
2. Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 2008; 10:R87; PMID:18928525; http://dx.doi.org/10.1186/bcr2157
3. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008; 13:394-406; PMID:18455123; http://dx.doi.org/10.1016/j.ccr.2008.03.007
4. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360:790-800; PMID:19228622; http://dx.doi.org/10.1056/ NEJMra0801289
5. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 2006; 66:5278-86; PMID:16707453; http://dx.doi.org/10.1158/0008-5472.CAN-05-4610
6. Hanneman J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006; 8:R-61; http://dx.doi.org/10.1186/bcr1613
7. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y, et al. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 2006; 25:2328-38; PMID:16314837; http://dx.doi.org/10.1038/sj.onc.1209265
8. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003; 100:5974-9; PMID:12714683; http://dx.doi.org/10.1073/pnas.0931261100
9. Castellana B, Escuin D, Peiró G, Garcia-Valdecasas B, Vázquez T, Pons C, et al. ASPN and GJB2 Are Implicated in the Mechanisms of Invasion of Ductal Breast Carcinomas. J Cancer 2012; 3:175-83; PMID:22514560; http://dx.doi.org/10.7150/jca.4120
10. Martins D, Sousa B, Lopes N, Gomes M, Veronese L, Albergaria A, et al. Molecular phenotypes of matched in situ and invasive components of breast carcinomas. Hum Pathol 2011; 42:1438-46; PMID:21450330; http://dx.doi.org/10. 1016/j.humpath.2010.08.024
11. Beck AH, Sangoi AR, Leung S, Marinelli RJ, Nielsen TO, van de Vijver MJ, et al. Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci Transl Med 2011; 3:ra113; PMID:22072638; http://dx.doi.org/10.1126/scitranslmed.3002564
12. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009; 11:R7; PMID:19187537; http://dx.doi.org/10.1186/bcr2222
13. Vargas AC, McCart Reed AE, Waddell N, Lane A, Reid LE, Smart CE, et al. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. Breast Cancer Res Treat 2012; 135:153-65; PMID:22718308; http://dx.doi.org/10.1007/s10549-012-2123-4
14. Schnitt SJ. Molecular biology of breast tumor progression: a view from the other side. Int J Surg Pathol 2010; 18(Suppl):170S-3S; PMID:20484285; http://dx.doi.org/10.1177/1066896910370773
15. Patani N, Martin LA, Reis-Filho JS, Dowsett M. The role of caveolin-1 in human breast cancer. Breast Cancer Res Treat 2012; 131:1-15; PMID:21901387; http://dx.doi.org/10.1007/s10549-011-1751-4
16. Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther 2009; 8:1071-9; PMID:19502809; http://dx.doi.org/10. 4161/cbt.8.11.8874
17. Witkiewicz AK, Kline J, Queenan M, Brody JR, Tsirigos A, Bilal E, et al. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle 2011; 10:1794-809; PMID:21521946; http://dx.doi.org/10.4161/cc.10.11.15675
18. Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, et al. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther 2010; 10:135-43; PMID:20431349; http://dx.doi.org/10.4161/cbt.10.2.11983
19. Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R, et al. Using the reverse Warburg effect to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 2012; 11:1108-17; PMID:22313602; http://dx.doi.org/10.4161/ cc.11.6.19530
20. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Bröer S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000; 350:219-27; PMID:10926847; http://dx.doi.org/10.1042/0264-6021:3500219
21. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, et al. Evidence for a stromal-epithelial lactate shuttle in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011; 10:1772-83; PMID:21558814; http://dx.doi.org/10. 4161/cc.10.11.15659
22. Miranda-Gonçalves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Pinheiro C, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol 2013; 15:172-88; PMID:23258846; http://dx.doi.org/10.1093/neuonc/nos298
23. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012; 7:423-67; PMID:22077552; http://dx.doi.org/10.1146/annurev-pathol-011811-120856
24. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174:2023-34; PMID:19411448; http://dx.doi.org/10.2353/ajpath.2009.080873
25. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007; 13:90-101; PMID:17200343; http://dx.doi.org/10.1158/1078-0432.CCR-06-1371
26. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009; 174:2035-43; PMID:19411449; http://dx.doi.org/10.2353/ajpath.2009. 080924
27. Goetz JG, Minguet S, Navarro-Lérida I, Lazcano JJ, Samaniego R, Calvo E, et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011; 146:148-63; PMID:21729786; http://dx.doi.org/10.1016/j.cell.2011.05.040
28. Bartholomew JN, Volonte D, Galbiati F. Caveolin-1 regulates the antagonistic pleiotropic properties of cellular senescence through a novel Mdm2/p53-mediated pathway. Cancer Res 2009; 69:2878-86; PMID:19318577; http://dx.doi.org/10.1158/0008-5472.CAN-08-2857
29. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, et al. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 2010; 9:1960-71; PMID:20495363; http://dx.doi.org/10. 4161/cc.9.10.11601
30. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, et al. Transcriptional evidence for the Reverse Warburg Effect in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, and Neuron-Glia Metabolic Coupling. Aging (Albany NY) 2010; 2:185-99; PMID:20442453
31. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012; 44:127-39; PMID:22407107; http://dx.doi.org/10. 1007/s10863-012-9428-1
32. Pinheiro C, Longatto-Filho A, Ferreira L, Pereira SM, Etlinger D, Moreira MA, et al. Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int J Gynecol Pathol 2008; 27:568-74; PMID:18753962; http://dx.doi.org/10.1097/PGP.0b013e31817b5b40